Summary: Researchers have identified a critical biological mechanism in the heart-brain axis that explains how a heart attack can reshape brain function and contribute to depression, anxiety, and cognitive decline. The team found that a highly reactive byproduct, methylglyoxal (MG), rises in the bloodstream after myocardial infarction and accumulates in brain regions that govern mood and memory, triggering inflammation and cellular damage.
This discovery clarifies a direct biochemical link between cardiac injury and post-event psychiatric and cognitive disorders, and it also introduces a promising peptide therapy designed to bind and neutralize the toxin before it harms vulnerable brain tissue.
Key Facts
- The Heart-Brain Axis: Neurological and cognitive problems that follow a heart attack appear to be driven, in part, by a cascade of molecular changes initiated when heart tissue is damaged.
- Toxic Byproduct Accumulation: After a myocardial infarction the body undergoes metabolic stress—reduced oxygen, inflammation, and altered metabolism—which causes methylglyoxal (MG), a reactive dicarbonyl previously studied in metabolic disease, to spike in blood and accumulate in brain regions responsible for emotion and cognition.
- Psychological and Cardiac Risk: Depression and anxiety occur up to three times more often in heart attack survivors than in the general population. Those who develop these conditions after an MI are up to 2.7 times more likely to experience a subsequent, potentially fatal cardiac event.
- Chronic Neurological Risk: By linking MG accumulation to localized neuroinflammation, microglial activation, and disruption of the blood-brain barrier, the study reveals a biological pathway that likely contributes to increased long-term dementia risk after cardiac injury.
- MG-Trapping Peptide: The research team at the University of Ottawa has created a peptide therapeutic that selectively binds methylglyoxal, preventing it from reacting with and damaging neural cells.
- Dual-System Protection: If clinical trials confirm efficacy, this therapy could protect brain health and reduce psychiatric symptoms after MI, which in turn may lower the elevated risk of repeat cardiac events tied to post-MI depression and anxiety.
Source: University of Ottawa
A new study led by researchers at the University of Ottawa advances our understanding of how myocardial infarction can alter brain function and increase risk for mood disorders and cognitive decline.
The study supports the heart-brain axis concept, showing that molecular signals triggered by cardiac injury can directly affect brain biology. While heart-brain interactions are complex and multifactorial, this research highlights methylglyoxal as a key reactive molecule that links heart injury to brain inflammation and dysfunction.
Brain inflammation after cardiac events
Methylglyoxal (MG) is produced in greater amounts after myocardial infarction due to tissue damage and metabolic stress. Elevated MG circulates in the bloodstream and deposits in specific brain regions—such as the brainstem and cortex—where it forms MG-derived advanced glycation end products (MG-AGEs). These modifications correlate with increased neuroinflammation, microglial and macrophage activation, and higher expression of receptors that respond to AGEs.
Clinically, patients who survive a heart attack face a substantially higher incidence of depression and anxiety. The study emphasizes how these psychiatric conditions are not only consequences of psychological stress but also have a biological driver that can worsen both brain and heart outcomes.
Charting new territory in heart-brain research
Published in Advanced Science, the findings may change how clinicians and researchers think about recovery after myocardial infarction and long-term neurological risk. By identifying MG accumulation and MG-AGE formation as contributors to neural inflammation and blood-brain barrier disruption, the research provides a mechanistic explanation for the observed rise in cognitive and emotional disorders after cardiac events.
“Methylglyoxal has been widely studied for its role in metabolic diseases such as diabetes, but less is known about its impact following cardiac injury,” says senior author Dr. Erik Suuronen, Full Professor in the Faculty of Medicine’s Department of Surgery and director of the BEaTs Research Program at the University of Ottawa Heart Institute. “Earlier work showed MG production by dying heart tissue after an MI; we predicted it would reach other organs, including the brain, and our results confirm that prediction.”
From discovery toward therapy
The study also explored therapeutic opportunities. The team has developed a peptide therapeutic that acts like a molecular sponge, recognizing and binding MG to prevent it from forming damaging AGEs. This MG-trapping peptide is now positioned for further testing to determine whether it can protect the brain following MI and reduce downstream psychiatric and cognitive consequences.
Dr. Suuronen notes that successful treatment of MG-driven brain inflammation could have dual benefits: preserving cognition and mood while reducing the feedback loop in which psychiatric stress further burdens the heart, thereby lowering the risk of later cardiac events.
Key Questions Answered:
A: This study shows a clear physical mechanism: dying heart tissue releases methylglyoxal, a reactive toxin that travels through the bloodstream and accumulates in brain regions that control emotion and memory. There it promotes inflammation and cellular damage that impair brain health and increase risk for mood disorders and cognitive decline.
A: The heart-brain axis works both ways. MG-driven brain damage can trigger chronic anxiety and depression, and those psychiatric conditions increase physiological stress on the cardiovascular system. Over time, this stress can raise the likelihood of a recurrent, potentially fatal heart event.
A: The peptide functions like a targeted molecular sponge: it is engineered to bind methylglyoxal selectively, neutralizing it before it can form damaging advanced glycation end products in the brain. By preventing MG from reacting with neural proteins and lipids, the peptide could reduce neuroinflammation and protect cognitive and emotional function.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by staff.
About this neurology research news
Author: Paul Logothetis
Source: University of Ottawa
Contact: Paul Logothetis – University of Ottawa
Image: The image is credited to Neuroscience News
Original Research: Open access. “Methylglyoxal Accumulation is Associated with Brain Inflammation after Myocardial Infarction with Sex and Regional Differences” by Ramis Ileri, Xixi Guo, Erik J. Suuronen. Advanced Science
DOI: 10.1002/advs.202522584
Abstract
Methylglyoxal Accumulation is Associated with Brain Inflammation after Myocardial Infarction with Sex and Regional Differences
Patients who suffer a myocardial infarction (MI) face a higher likelihood of developing neurological disease and cognitive impairment, yet the mechanisms connecting heart injury to brain outcomes have been incompletely defined.
Methylglyoxal (MG), a reactive dicarbonyl linked to both cardiovascular and neurological conditions, forms MG-derived advanced glycation end products (MG-AGEs) that accumulate in the heart and circulation after MI, making MG a compelling target for studying the heart-brain axis.
This study reports that MG-AGEs accumulate in the mouse brain as early as 6 hours and persist at 7 days after MI, with the highest levels in the brainstem and notable expression in the cortex. Sex differences emerged: males exhibited higher MG-AGE expression than females in most brain regions examined.
MG-AGE accumulation correlated with increased neuroinflammation, including more activated microglia and macrophages, upregulation of AGE receptors, elevated inflammatory markers (NF-κB and TNF-α), and reductions in blood-brain barrier tight junction proteins.
Together, these findings define a novel MG-mediated mechanism—with sex- and region-specific differences—that likely contributes to heart-brain interactions after MI and highlights a promising therapeutic target for preventing neurological impairment associated with heart disease.